Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

StatusUnknown
PhasePhase 1/2
Started

Record status This record was last updated September 19, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Primary completion date: Aug 2024 to Aug 2025
    • Study completion date: Dec 2024 to Dec 2025
    v15
  3. Primary completion date: Jul 2023 to Aug 2024
    • Study completion date: Dec 2023 to Dec 2024
    v14
  4. Primary completion date: Sep 2022 to Jul 2023
    • Study completion date: Jun 2023 to Dec 2023
    v13
  5. Primary completion date: Jan 2022 to Sep 2022
    • Study completion date: Jun 2022 to Jun 2023
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary completion date: Aug 2021 to Jan 2022
    • Study completion date: Feb 2022 to Jun 2022
    v11
  2. Primary completion date: Jan 2021 to Aug 2021
    • Study completion date: Jul 2021 to Feb 2022
    v10
  3. Primary completion date: May 2020 to Jan 2021v9 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 52 to confirmed 30
    • Study completion date: Jul 2020 to Jul 2021
    • Site details revised at 3 of 3 sites
  4. Lead sponsor: University of California, Davis to Joseph Tuscanov8
  5. 2 versions Re-verified since Jan 5, 2018, no change to tracked fieldsv6-v7
  6. Study sites: 2 to 3v5
  7. Re-verified, no change to tracked fieldsv4
  8. Collaborators revised (2)v3
  9. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I/II trial studies the side effects and best dose of clarithromycin when given together with ixazomib citrate, pomalidomide, and dexamethasone and to see how well it works in treating patients with multiple myeloma that has not responded to previous treatment. Biological therapies, such as clarithromycin, pomalidomide, and dexamethasone, use substances made from living organisms that may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving clarithromycin with ixazomib citrate, pomalidomide and dexamethasone may be a better treatment for patients with multiple myeloma.
Trial Details
NCT Number NCT02542657
Lead Sponsor Joseph Tuscano
Collaborators: Takeda, Celgene
Conditions
(from sponsor)		 Myeloma
Related terms Neoplasms, Plasma Cell
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov